» Articles » PMID: 26794744

Biphasic Release of Gentamicin from Chitosan/fucoidan Nanoparticles for Pulmonary Delivery

Overview
Journal Carbohydr Polym
Specialty Biochemistry
Date 2016 Jan 23
PMID 26794744
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Gentamicin (GM), one of the most commonly used aminoglycoside antibiotics, has been used for treating pneumonia; however, the applicability of GM is limited by its bioavailability and toxic side effects. This study used chitosan (CS)/fucoidan (F) nanoparticles (NPs) to develop a nanoformulation for pulmonary delivery of GM, presenting a biphasic release feature. The NPs exhibited a zero-order release of GM for the first 10h, followed by a sustained release of up to 72h, attaining a value of 99%. The GM-loaded CS/F NPs provide multiple antimicrobial capabilities against Klebsiella pneumoniae, including the CS and biphasic release of GM. Compared with the intravenous administration of free GM (0.5mg/kg), the intratracheal administration of GM-loaded CS/F NP (0.27mg/kg) presented a superior area under the concentration-time curve/minimum inhibitory concentration ratio, indicating the simultaneous improvement of antimicrobial efficacy and elimination of systemic toxicity. These results suggested that CS/F NPs are potential carriers in pulmonary delivery of GM for pneumonia treatment.

Citing Articles

New Insights into Antiviral Natural Formulations: Biopolymeric Films for the Prevention and Treatment of a Wide Gamma of Viral Infections.

Ayala-Pena V, Jaimes A, Conesa A, Garcia C, Sepulveda C, Dellatorre F Viruses. 2025; 17(2).

PMID: 40006971 PMC: 11861794. DOI: 10.3390/v17020216.


Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications.

Alwahsh W, Sahudin S, AlKhatib H, Bostanudin M, Alwahsh M Curr Drug Targets. 2024; 25(7):492-511.

PMID: 38676513 DOI: 10.2174/0113894501301747240417103321.


State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives.

Costabile G, Conte G, Brusco S, Savadi P, Miro A, Quaglia F Pharmaceutics. 2024; 16(3).

PMID: 38543241 PMC: 10975237. DOI: 10.3390/pharmaceutics16030347.


Excipients for Novel Inhaled Dosage Forms: An Overview.

Yousry C, Goyal M, Gupta V AAPS PharmSciTech. 2024; 25(2):36.

PMID: 38356031 DOI: 10.1208/s12249-024-02741-w.


Chitosan nanoparticle toxicity: A comprehensive literature review of and assessments for medical applications.

Zoe L, David S, Rajabalaya R Toxicol Rep. 2024; 11:83-106.

PMID: 38187113 PMC: 10767636. DOI: 10.1016/j.toxrep.2023.06.012.